"morphological changes of the saccule : elongation (height >1.5-1.6 mm) 11,12 , increased width (>1.4mm) or a round shape appearance with isolated width increase11."
"morphological changes of the saccule : elongation (height >1.5-1.6 mm) 11,12 , increased width (>1.4mm) or a round shape appearance with isolated width increase11."
"morphological changes of the saccule : elongation (height >1.5-1.6 mm) 11,12 , increased width (>1.4mm) or a round shape appearance with isolated width increase11."
"Increased mean utricle area and/or utricle to vestibule area ratio23."
"morphological changes of the saccule : elongation (height >1.5-1.6 mm) 11,12 , increased width (>1.4mm) or a round shape appearance with isolated width increase11."
"Increased mean utricle area and/or utricle to vestibule area ratio23."
"Off-label warning: The use of gadolinium-based contrast agents for intratympanic administration is not approved by regulatory agencies such as the FDA."
"Tumarkin otolithic crisis: sudden drop attacks 16"
"Tullio phenomenon may rarely be experienced 8"
"Increased mean utricle area and/or utricle to vestibule area ratio23."
"Off-label warning: The use of gadolinium-based contrast agents for intratympanic administration is not approved by regulatory agencies such as the FDA."
"Off-label warning: The use of gadolinium-based contrast agents for intratympanic administration is not approved by regulatory agencies such as the FDA."
Expected headings
"Non-contrast-enhanced MRI"
"Contrast-enhanced MRI"
"The prevalence of Ménière disease is approximately 0.2% 15, although there are concerns regarding overdiagnosis 17. There is a slight female predilection 15."
"audiometrically documented low- to medium-frequency sensorineural hearing loss in one ear, defining the affected ear on at least one occasion before, during or after one of the episodes of vertigo"
"fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear"
"fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear"